Search

Your search keyword '"de Wreede, Liesbeth C."' showing total 5 results
Start Over Author "de Wreede, Liesbeth C." Topic myelofibrosis
5 results on '"de Wreede, Liesbeth C."'

1. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.

Author

Robin, Marie, Gras, Luuk, Koster, Linda, Gagelmann, Nico, van Gorkom, Gwendolyn, Ederr, Matthias, Itälä‐Remes, Maija, Zuckerman, Tsila, Beguin, Yves, Schaap, Nicolaas, Drozd‐Sokolowska, Joanna, Raj, Kavita, Hayden, Patrick J., de Wreede, Liesbeth C., Battipaglia, Giorgia, Polverelli, Nicola, Czerw, Tomasz, Hernandez Boluda, Juan Carlos, Kröger, Nicolaus, and Yakoub‐agha, Ibrahim

Subjects
STEM cell transplantation, MYELOFIBROSIS, HEMATOPOIETIC stem cell transplantation, HEPATIC veno-occlusive disease, LIVER
Abstract

This article examines the occurrence of liver complications in patients with myelofibrosis who undergo allogeneic hematopoietic stem cell transplantation (HSCT). The study found that liver adverse events (AEs) were more common than expected, with 64% of patients experiencing liver AEs within the first 100 days after HSCT. The most common liver AEs were caused by the conditioning regimen. Risk factors for liver toxicity included worse performance status, higher comorbidity index, and higher prognostic scoring system score. The study also found that hyperbilirubinemia and hepatic graft-versus-host disease were associated with increased mortality. The text emphasizes the importance of monitoring liver complications in HSCT patients and suggests using imaging and biopsies to determine the cause and guide treatment. The study included various factors in the analysis and was approved by the appropriate ethics committee. [Extracted from the article]

Published
2024
Full Text
View/download PDF

2. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation

Author

Gagelmann, Nico, Eikema, Diderik-Jan, de Wreede, Liesbeth C, Koster, Linda, Wolschke, Christine, Arnold, Renate, Kanz, Lothar, McQuaker, Grant, Marchand, Tony, Socié, Gerard, Bourhis, Jean Henri, Mohty, Mohamad, Cornelissen, Jan J, Chevallier, Patrice, Bernasconi, Paolo, Stelljes, Matthias, Rohrlich, Pierre-Simon, Fanin, Renato, Finke, Jürgen, Maertens, Johan, Blaise, Didier, Itälä-Remes, Maija, Labussière-Wallet, Hélène, Robin, Marie, McLornan, Donal, Chalandon, Yves, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, CMWP of the European Society for Blood and Marrow Transplantation, Hematology, and Medical Oncology

Subjects
Adult, medicine.medical_specialty, Essential thrombocythemia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Polycythemia vera, Internal medicine, Humans, Transplantation, Homologous, Medicine, Allogeneic stem cell transplantation, Secondary myelofibrosis, Hematology, Transplantation, Myelofibrosis, Polycythemia Vera, Survival analysis, Aged, ddc:616, Framingham Risk Score, business.industry, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Treatment Outcome, Primary Myelofibrosis, International Prognostic Scoring System, 030220 oncology & carcinogenesis, Cohort, business, Thrombocythemia, Essential, 030215 immunology
Abstract

We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) from the European Society for Blood and Marrow Transplantation registry undergoing transplantation from matched siblings or unrelated donors. Furthermore, we aimed to test its prognostic performance in comparison with the Dynamic International Prognostic Scoring System (DIPSS). Score performance was analyzed using the concordance index (C): the probability that a patient who experienced an event had a higher risk score than a patient who did not (C > .5 suggesting predictive ability). Median follow-up of the total cohort was 41 months (range, 34 to 54), 45 months in post-PV and 38 months in post-ET myelofibrosis. Survival at 1, 2, and 4 years was 70% (95% CI, 63% to 77%), 61% (95% CI, 53% to 69%), and 52% (95% CI, 43% to 61%) for the total cohort; 70% (95% CI, 59% to 80%), 61% (95% CI, 49% to 73%), and 51% (95% CI, 38% to 64%) for post-PV; and 71% (95% CI, 61% to 81%), 61% (95% CI, 50% to 72%), and 54% (95% CI, 42% to 66%) for post-ET myelofibrosis (P = .78). Overall, the DIPSS was not significantly predictive of outcome (P = .28). With respect to the MYSEC-PM, overall survival at 4 years was 69% for the low-risk, 55% for the intermediate 1-risk, 47% for the intermediate 2-risk, and 22% (0% to 45%) for the high-risk groups. The prognostic model was predictive of survival overall (P = .05), whereas groups with intermediate 2 and high risk showed no significant difference (P = .44). Assessment of prognostic utility yielded a C-index of .575 (95% CI, .502 to .648) for the DIPSS, whereas assessment of the MYSEC-PM resulted in a C-statistics of .636 (95% CI, .563 to .708), indicating improvement in prediction of post-transplant survival using the new MYSEC-PM. In addition, transplantations from an unrelated donor in comparison with an HLA-identical sibling showed worse outcome (P = .04), and transplant recipients seropositive for cytomegalovirus in comparison with seronegative recipients (P = .01) showed worse survival. In conclusion, incorporating transplant-specific and clinical and mutational information together with the MYSEC-PM may enhance risk stratification. ispartof: Biol Blood Marrow Transplant vol:25 issue:6 pages:e204-e208 ispartof: location:United States status: published

Published
2019

3. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Author

Robin, Marie, De Wreede, Liesbeth C., Wolschke, Christine, Schetelig, Johannes, Eikema, Diderik-Jan, Van Lint, Maria Teresa, Knelange, Nina Simone, Beelen, Dietrich, Brecht, Arne, Niederwieser, Dietger, Vitek, Antonin, Bethge, Wolfgang, Arnold, Renate, Finke, Jürgen, Volin, Liisa, Yakoub-Agha, Ibrahim, Nagler, Arnon, Poiré, Xavier, Einsele, Hermann, Chevallier, Patrice, Holler, Ernst, Ljungman, Per, Robinson, Stephen, Radujkovic, Alekxandar, McLornan, Donal, Chalandon, Yves, Kröger, Nicolaus, Eikema, Dirk-Jan, Radujkovic, Aleksandar, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, HUS Comprehensive Cancer Center, Hematologian yksikkö, and Department of Oncology

Subjects
Male, Ruxolitinib, BLOOD, Multivariate analysis, Survival, medicine.medical_treatment, Medizin, Graft vs Host Disease, Hematopoietic stem cell transplantation, Disease, PROGNOSTIC SCORING SYSTEM, GRUPPO-ITALIANO, MIDOLLO-OSSEO, 0302 clinical medicine, Risk Factors, Midollo-Osseo, RUXOLITINIB, Registries, SOCIETE FRANCAISE, Cause of death, ddc:616, education.field_of_study, Remission Induction, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, 3. Good health, Blood, Treatment Outcome, SURVIVAL, Female, medicine.drug, Adult, medicine.medical_specialty, LATE MORTALITY, Population, Article, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, ddc:610, education, Myelofibrosis, Aged, EUROPEAN GROUP, business.industry, medicine.disease, Transplantation, LATE DEATHS, Primary Myelofibrosis, 3121 General medicine, internal medicine and other clinical medicine, Multivariate Analysis, Myeloproliferative Neoplasms, Neoplasm Recurrence, Local, business, 030215 immunology
Abstract

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged = 65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.

Published
2019

4. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Author

Raj, Kavita, Eikema, Diderik-Jan, McLornan, Donal P, Olavarria, Eduardo, Blok, Henric-Jan, Bregante, Stefania, Ciceri, Fabio, Passweg, Jakob, Ljungman, Per, Schaap, Nicolaas, Carlson, Kristina, Zuckerman, Tsila, de Wreede, Liesbeth C., Volin, Liisa, Koc, Yener, Diez-Martin, Jose Luis, Brossart, Peter, Wolf, Dominik, Blaise, Didier, and Bartolomeo, Paolo Di

Subjects
*STEM cell transplantation, *PROGRESSION-free survival, *MYELOFIBROSIS, *BONE marrow, *ALEMTUZUMAB, *BLOOD, *TRANSPLANTATION of organs, tissues, etc.
Abstract

Highlights • We performed a retrospective review of 56 myelofibrosis patients transplanted from mismatched family donors. • Neutrophil engraftment at a median of 20days was observed in 82%. • Low rates of acute GVHD grades II to IV were observed in 28% (16% to 40%) and grades III to IV in 9% (2% to 16%). • Chronic GVHD at 1 year was found in 45% (32% to 58%). • Overall survival at 2years was 56% (41% to 70%). Abstract This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

5. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Author

Paolo Bartolomeo, Tsila Zuckerman, Liisa Volin, Peter Brossart, Yener Koc, Donal P. McLornan, Jakob Passweg, Per Ljungman, Nicolaus Kröger, Dominik Wolf, Liesbeth C. de Wreede, Fabio Ciceri, Stefania Bregante, Kavita Raj, Kristina Carlson, Ibrahim Yakoub-Agha, Didier Blaise, Antonin Vitek, Eduardo Olavarria, Henric Jan Blok, José Luis Díez-Martín, Marie Robin, Nicolaas Schaap, Yves Chalandon, Diderik Jan Eikema, Raj, Kavita, Eikema, Diderik-Jan, Mclornan, Donal P, Olavarria, Eduardo, Blok, Henric-Jan, Bregante, Stefania, Ciceri, Fabio, Passweg, Jakob, Ljungman, Per, Schaap, Nicolaa, Carlson, Kristina, Zuckerman, Tsila, de Wreede, Liesbeth C., Volin, Liisa, Koc, Yener, Diez-Martin, Jose Lui, Brossart, Peter, Wolf, Dominik, Blaise, Didier, Bartolomeo, Paolo Di, Vitek, Antonin, Robin, Marie, Yakoub-Agha, Ibrahim, Chalandon, Yve, Kroger, Nicolaus, Clinicum, Department of Oncology, and HUS Comprehensive Cancer Center

Subjects
Male, Transplantation Conditioning, Databases, Factual, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Graft vs Host Disease, Myelofibrosis, Gastroenterology, HEMATOLOGIC MALIGNANCIES, 0302 clinical medicine, Recurrence, CYCLOPHOSPHAMIDE, Cumulative incidence, Societies, Medical, Bone Marrow Transplantation, Incidence (epidemiology), Graft Survival, Hematopoietic Stem Cell Transplantation, Myelofibrosi, Hematology, Middle Aged, Mismatched related donor, 3. Good health, Fludarabine, Europe, 030220 oncology & carcinogenesis, Histocompatibility, Female, medicine.drug, Adult, medicine.medical_specialty, 3122 Cancers, ThioTEPA, POLYCYTHEMIA-VERA, Haploidentical, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, Family, Aged, Retrospective Studies, Peripheral Blood Stem Cell Transplantation, Transplantation, Neutrophil Engraftment, business.industry, medicine.disease, Survival Analysis, ENGRAFTMENT, Primary Myelofibrosis, 3121 General medicine, internal medicine and other clinical medicine, UMBILICAL-CORD BLOOD, business, LEUKEMIA, Busulfan, 030215 immunology
Abstract

Contains fulltext : 202803.pdf (Publisher’s version ) (Open Access) This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34(+) cell dose was 4.8x10(6)/kg (range, 1.7 to 22.9; n=43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results